US 5,212,168 AGranted

Method of and solution for treating glaucoma

AssigneeNew England Medical Center Hospital, Inc.

InventorBernard Schwartz

Life of this patent

Estimating the term…

Loading patent…

Abstract

A method for treating glaucoma consisting of exposing the eye to a corticosteroid and an alpha or a beta adrenergic agent to the eye which acts to decrease ocular pressure. Useful adrenergic agents include beta agonist antagonists, including, for example, epinephrine, dipivalyl epinephrine, betaxolol, levobunolol, timolol, and an alpha adrenergic agonist, including apraclonidine hydrochloride. Useful steroids, which are preferably applied topically, include dexamethasone, prednisolone, cortisone, and triamcinolone. The beta adrenergic agent is administered at a concentration between 10% and 20% of the concentration that the agent is administered in its normal use. The corticosteroid is administered at a concentration between 5% and 10% of the concentration that the corticosteroid is administration in its normal use.

Claims5

Dependent claims

A method for treating elevated intraocular pressure in a mammalian eye comprising:

administering to the eye a therapeutically effective amount of a corticosteroid and an alpha adrenergic agent;
said corticosteroid selected from the group consisting of dexamethasone having a concentration from 0.0005 to 0.01%, prednisolone having a concentration from 0.0005% to 0.1%, hydrocortisone having a concentration from 0.0025 to 0.05%, cortisone having a concentration from 0.0125 to 0.25%, fluorometholone having a concentration from 0.0005 to 0.01%, betamethasone having a concentration from 0.0005 to 0.01%, methyl prednisolone having a concentration from 0.04 to 0.8%, triamcinolone having a concentration of 0.0005 to 0.01%, and their physiologically acceptable salts;
said alpha adrenergic agent being apraclonidine hydrochloride having a concentration ranging from about 0.1% to 0.25% and its physiologically acceptable salts;
the concentration of said corticosteroid and said alpha adrenergic agent being selected to produce a prolonged decrease in intraocular pressure while minimizing undesirable side effects of said corticosteroid and said alpha adrenergic agent.

1 more element

Dependencies are inferred from the claim text.